Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients

Ali, Arwa; Ueno, Takayuki; Tanaka, Sunao; Takada, Masahiro; Ishiguro, Hiroshi; Abdellah, Ashraf Z.; Toi, Masakazu

doi:10.1016/j.ejca.2011.06.015

Cited by 28 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in accordance with those by Wierzbowska et al, who observed that the levels of CECs and EPCs were significantly higher in AML patients than in the control group by a 17-and 18-fold, respectively (13). This is in concordance with previous studies in multiple myeloma (MM), metastatic carcinoma, myelodysplastic syndrome, gastrointestinal stromal disease (GIST), hepatocellular carcinoma, breast cancer, non-Hodgkin's lymphoma (NHL), myelofibrosis and chronic lymphocytic leukemia (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17).…”

Section: Discussionsupporting

confidence: 82%

“…by the use of different chemotherapy agents (11). Additionally, CECs and EPCs could be used as a novel marker for minimal residual disease in chronic myeloid leukemia, as reported by Wu et al (12).…”

Section: Circulating Endothelial Cells and Their Progenitors In Acutementioning

confidence: 75%

“…Furthermore, the levels of CECs have been correlated to tumor stage and prognosis (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Circulating endothelial cells and their progenitors in acute myeloid leukemia

et al. 2016

View full text Add to dashboard Cite

Abstract. Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the accumulation of immature myeloid progenitor cells in the bone marrow. Studies are required to investigate the prognostic and predictive value of surrogate biomarkers. Given the importance of angiogenesis in oncology in terms of pathogenesis as well as being a target for treatment, circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) are promising candidates to serve as such markers. The aim of the present study was to quantify CECs and EPCs in patients with AML at initial diagnosis and following induction chemotherapy, and to correlate these findings with the response to treatment in AML patients. The present study included 40 patients with de novo AML and 20 age-and gender-matched healthy controls. CECs and EPCs were evaluated by flow cytometry at initial diagnosis and after induction chemotherapy (3+7 protocol for AML other than M3 and all-trans-retinoic acid plus anthracycline for M3 disease). CECs and EPCs were significantly higher in AML patients at diagnosis and after induction chemotherapy than in controls. After induction chemotherapy, CECs and EPCs were significantly decreased compared with the levels at initial diagnosis. Patients who achieved complete response (n=28) had lower initial CEC and EPC levels compared with patients who did not respond to treatment. These results suggest that CEC levels are higher in AML patients and may correlate with disease status and treatment response. Further investigations are required to better determine the predictive value and implication of these cells in AML management.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Circulating Endothelial Cells and Their Progenitors In Acutementioning

confidence: 75%

See 1 more Smart Citation

Circulating endothelial cells and their progenitors in acute myeloid leukemia

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some studies are not suitable for deriving the predictive value due to their small sample size [13,14,15,16]. We focused on recent data showing that CTCs may represent novel tumor biomarkers for predicting the response to NCT in LABC patients.…”

Section: Introductionmentioning

confidence: 99%

Are Changes in Circulating Tumor Cell (CTC) Count Associated with the Response to Neoadjuvant Chemotherapy in Local Advanced Breast Cancer? A Meta-Analysis

Fei

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

Introduction: Circulating tumor cells (CTCs) represent a biomarker for tumor progression and monitoring therapeutic effects. We evaluated the association between the changes in CTC count and the pathological response to neoadjuvant chemotherapy (NCT) for local advanced breast cancer (LABC) patients. Methods: PubMed, EBSCO, Web of Science, conference proceedings and key trials for the period 1998-2012 were searched. We used the hazard ratio (HR) to evaluate the variation in the number of CTCs to predict the response to NCT in LABC patients. All data from each study were investigated using either fixed- or random-effect models and were analyzed using Stata software. Results: There was no between-study heterogeneity in pathological complete response (pCR) (heterogeneity chi-squared = 0.02 (df = 1), I² = 0.0%, p = 0.877). Our meta-analysis showed that the change (decrease or increase) in CTC number in LABC patients during NCT was not correlated with pCR (HR = 0.918, 95% confidence interval 0.650-1.295; p = 0.877). Conclusion: The results of the current meta-analysis indicate that there is no association between the decrease of CTC number and pCR after NCT. According to our results, a decrease in the CTC count after NCT in LABC patients did not indicate that they had an improved response to NCT. However, more randomized clinical trials are needed to confirm this conclusion.

show abstract

“…Moreover, it may be used in the field of diagnostic follow-up, determining the response to treatment and prognosis of the disease (Ali et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Expression of Ki67 and CD105 as Proliferation and Angiogenesis Markers in Salivary Gland Tumors

Andisheh-Tadbir¹,

Pardis²,

Ashkavandi³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To investigate the association between CD105 and tumor cell proliferation in salivary gland tumors. Methods: In this study, 59 samples of salivary tumors from Khalili Hospital archive, including 20 cases of pleomorphic adenoma (PA), 20 cases of mucoepidermoid carcinoma (MEC) and 19 cases of adenoid cystic carcinoma, as well as 10 cases of normal salivary gland tissue, were reviewed by immunohistochemistry (IHC) for CD105 and Ki67 staining. Results: CD105 positive vessels were absent in normal salivary gland tissue in the vicinity of tumors (51.6% of all tumors were positive). There was a statistically significant difference in frequency of CD105 staining between PA and malignant tumors and between four groups of different lesions (p<0.000) being highest in MEC. Intratumoral microvessel density was also elevated in malignant neoplasms (2.61±3.1) as compared to PA (0.46±0.6). Normal salivary glands did not express Ki67. There was a statistically significant difference in frequency and percentage of Ki67 immunoreactivity in malignant neoplasms (86.5% and 10.7±10.8 respectively) compared to PA (50% and 0.78±0.2) and among the four groups values were highest in MEC (p<0.000). Conclusion: n this study, it was observed a higher rate of angiogenesis and cellular proliferation was noted in malignant tumors compared to benign tumors, but no correlation was observed between these two markers.

show abstract

Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients

Abstract: Baseline CEC, in particular CD34(+)CEC, counts and the CD34 positive rate might be useful for the prediction of treatment response of preoperative chemotherapy in patients with operable breast cancer.

Cited by 28 publications

References 28 publications

Circulating endothelial cells and their progenitors in acute myeloid leukemia

Circulating endothelial cells and their progenitors in acute myeloid leukemia

Are Changes in Circulating Tumor Cell (CTC) Count Associated with the Response to Neoadjuvant Chemotherapy in Local Advanced Breast Cancer? A Meta-Analysis

Expression of Ki67 and CD105 as Proliferation and Angiogenesis Markers in Salivary Gland Tumors

Contact Info

Product

Resources

About